Qinlock
Active Ingredient(s): RipretinibFDA Approved: * May 15, 2020
Pharm Company: * DECIPHERA PHARMS
Category: Cancer
Ripretinib, sold under the brand name Qinlock, is a medication for the treatment of adults with advanced gastrointestinal stromal tumor (GIST), a type of tumor that originates in the gastrointestinal tract.[2][3] It is taken by mouth.[2][3] Ripretinib inhibits the activity of the kinases KIT and PDGFRA, which helps keep cancer cells from growing.[3] The most common side effects include alopecia (hair loss), fatigu... [wikipedia]
* May have multiple approval dates, manufacturers, or labelers.